Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

882302

registered interest
date	13/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how the £86 million to support innovators and the NHS in overcoming barriers to getting new, innovative technologies to patients as part of the Accelerated Access Review will be allocated.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	135438
answer	answer is ministerial correction date of answer 18/04/2018 answer text <p>£86 million has been allocated by the Department for Business, Energy and Industrial Strategy and the Department of Health and Social Care as follows:</p><p> </p><p>- £39 million to improve local adoption and uptake of innovative medical technologies through the 15 Academic Health Science Networks, who will be given increased capacity to help innovative products find the right support and to promote regional adoption and spread;</p><p>- £35 million over four years to encourage and support innovators to develop more world-leading digital solutions. Through the Digital Health Technology Catalyst, small and medium-sized enterprises (SME)-led projects will be supported to develop the evidence base required to launch their products in the National Health Service;</p><p>- £6 million to help the NHS to adopt and integrate new technologies into everyday practice, through the Pathway Transformation Fund; and</p><p>- £6 million over three years from the Industrial Strategy Challenge Fund to support SMEs to address the difficulties they face in getting their new medicines and medical technologies adopted in the market by supporting them to gather the evidence required to prove clinical efficacy.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 18/04/2018 09:57:59 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4658 label Biography information for Alex Sobel

850719

registered interest
date	27/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when the first treatments and technologies chosen for the Accelerated Access Pathway will be available for the NHS to use.
tabling member constituency	Chesham and Amersham
tabling member printed	Dame Cheryl Gillan
uin	129961
answer	answer is ministerial correction date of answer 05/03/2018 answer text <p>As set out in the response to the Accelerated Access Review, the Accelerated Access Pathway was established with the purpose of getting those innovations that we believe will be truly transformative to patients more quickly. The pathway will open in April for product selection. Exact timing of when the first products will reach the National Health Service will depend on those products selected. The Pathway will be open to medicines, devices, diagnostics and digital products.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/03/2018 15:57:36 answering member 4067 label Biography information for Steve Brine
tabling member	18 label Biography information for Dame Cheryl Gillan

833871

registered interest
date	30/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the criteria to access the accelerated access pathway.
tabling member constituency	North Tyneside
tabling member printed	Mary Glindon
uin	125629
answer	answer is ministerial correction date of answer 07/02/2018 answer text <p>As set out in the response to the Accelerated Access Response published in November 2017, the pathway will be developed and owned by the newly created Accelerated Access Collaborative (AAC), a partnership between the National Health Service, industry, and clinical and patient representatives. The AAC met for the first time on 31 January and it will be that group’s responsibility to determine the criteria for the pathway. We anticipate that the AAC will publish further details on the process and criteria for the pathway ahead of the pathway opening in April 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/02/2018 14:05:49 answering member 4067 label Biography information for Steve Brine
tabling member	4126 label Biography information for Mary Glindon

818651

registered interest
date	08/01/2018
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Government response to the Accelerated Access Review published in November 2017, what plans his Department has to streamline existing routes to market for medical technologies, devices and diagnostics.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	121415
answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>We are introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. A new Accelerated Access Collaborative (AAC) chaired by Sir Andrew Witty, will develop and own the Accelerated Access Pathway which will be operational from April 2018. All products including medical technologies, devices and diagnostics will be eligible for selection. In addition to the new Pathway, the AAC will also make recommendations to the Government and its partners about opportunities to further streamline existing routes to market.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 12:04:46 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

806540

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect of implementation of the recommendations of the Accelerated Access review on services to people with (a) Cystic Fibrosis and (b) other long-term conditions; and will he make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	119616
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the effect of implementation on any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 16:49:37 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

806545

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential benefits for people with long-term conditions such as cystic fibrosis of implementing the recommendations of the accelerated access review; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	119621
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the benefits for any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 16:48:34 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

784929

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of products that will be considered for breakthrough status through the Accelerated Access Pathway in the next financial year.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	111599
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>As set out in the response to the Accelerated Access Review, published on 3 November, we anticipate that around five breakthrough products will be selected each year. The Accelerated Access Pathway will be open to products from April 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 16:59:28 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

784930

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the pharmaceutical industry on the cost effectiveness criteria for new treatments seeking breakthrough designation through the Accelerated Access Pathway.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	111600
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>Ministers and officials from the Department meet regularly with the pharmaceutical industry to discuss policy development and implementation. Engagement will continue on the implementation of the Accelerated Access pathway and criteria for breakthrough products.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 17:26:42 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

784940

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the capacity of the Accelerated Access Pathway to consider treatments for rare diseases, including muscle-wasting conditions, to be considered for fast-track breakthrough designation.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	111598
answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>The Accelerated Access Collaborative (AAC) will define the criteria for breakthrough products in the coming months. As set out in the response to the Accelerated Access Response, the AAC will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 16:56:25 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

771344

registered interest
date	16/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to implement the recommendations of the Accelerated Access Review, published on 24 October 2016.
tabling member constituency	Wigan
tabling member printed	Lisa Nandy
uin	107744
answer	answer is ministerial correction date of answer 24/10/2017 answer text <p>The Government and its partners are carefully considering the recommendations in the Accelerated Access Review. A response will be published shortly, where we will outline plans for improving patient access to transformative treatments at a price the National Health Service can afford.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/10/2017 14:29:57 answering member 4067 label Biography information for Steve Brine
tabling member	4082 label Biography information for Lisa Nandy